Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pierre Borczuk who wrote (305)	2/6/2004 1:57:17 PM
From: Jim Oravetz	Read Replies (1) of 370

Vion Provides Update On Clinical Trials Of Triapine(R) As A Single Agent DOW JONES NEWSWIRES NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) reported there was "some single agent activity" during Phase II trials of its anticancer product Triapine in head and neck cancer patients. Among 32 neck head and neck cancer patients with recurrent or metastatic disease, one patient achieved a partial response and nine had stable disease after four courses. The drug wasn't effective in the remaining patients, a company spokesman said. He added that in the long run, most drugs are used in combination. The company has decided to end a separate Phase II clinical trial of Triapine in patients with prostate cancer in order to focus resources on its two ongoing Phase II studies of Triapine in combination with gemcitabine. These trials would focus on pancreatic cancer and non-small-cell lung cancer. "The focus of our development strategy for Triapine continues to be in combination with other approved anticancer agents," said Mario Sznol, vice president, clinical affairs, in the release. Shares of Vion closed Thursday at $2.85, up 15 cents a share, or 5.6%.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next